Skip to main content
Kexing Biopharm logo

Kexing Biopharm — Investor Relations & Filings

Ticker · 688136 ISIN · CNE100006ZG6 LEI · 529900Z34Q1M9A907771 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 756 across all filing types
Latest filing 2023-01-30 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 688136

About Kexing Biopharm

https://www.kexingbiopharm.com/

Kexing Biopharm is an innovative biopharmaceutical enterprise engaged in the research, development, production, and sales of recombinant protein drugs and micro-ecological preparations. The company focuses on developing treatments for therapeutic areas including kidney diseases, oncology, antiviral therapy, autoimmune disorders, metabolic diseases, and degenerative diseases. A key product in its portfolio is Erythropoietin Injection. Kexing Biopharm maintains a comprehensive quality system that aligns with international standards, covering the entire drug lifecycle from production and quality control to release and transportation, ensuring the continuous and stable manufacturing of safe and effective medicines.

Recent filings

Filing Released Lang Actions
2023年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement from the 2023 first extraordinary shareholders meeting of 科兴生物制药股份有限公司. It details the meeting date, attendance, voting results on specific proposals including the reappointment of the 2022 audit firm and amendments to the company bylaws, and includes legal witness statements. The content is focused on the official announcement of voting results from a shareholders meeting rather than the meeting materials or the full report itself. The document length is relatively short (2569 characters) and it serves as a formal disclosure of voting outcomes. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2023-01-30 Chinese
北京市嘉源律师事务所关于科兴生物制药股份有限公司2023年第一次临时股东大会的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, procedures, and validity of a company's 2023 first extraordinary general meeting (临时股东大会). It details the meeting's notice, attendance, voting procedures, and results. The document does not contain financial statements or performance data, nor is it a report of financial results or management discussion. It is a legal opinion related to a shareholder meeting, specifically focusing on the legality and procedural correctness of the meeting and voting. This type of document is best classified as a Regulatory Filing (RNS) because it is a legal opinion letter related to corporate governance and shareholder meeting compliance, and does not fit into other categories such as AGM Information (which would be presentations/materials shared at the AGM) or Declaration of Voting Results (which would be the official voting results announcement). The document is also under 5,000 characters and is a standalone legal opinion, not the meeting materials themselves.
2023-01-30 Chinese
2023年第一次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled '2023 年第一次临时股东大会 会议材料' which translates to '2023 First Extraordinary General Meeting (EGM) Meeting Materials'. It contains detailed meeting notices, agenda, proposals for shareholder approval including reappointment of the audit firm and amendments to the company bylaws. The content is typical of materials distributed to shareholders prior to or during a shareholder meeting to inform and facilitate voting on corporate matters. There is no financial data or earnings information, nor is it a transcript or announcement of voting results. This matches the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual or Extraordinary General Meeting. The document length (15,000 characters) and detailed content confirm it is the meeting materials themselves, not just an announcement or summary.
2023-01-18 Chinese
自愿披露关于人干扰素α1b吸入溶液I期临床试验完成首例受试者入组的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the completion of the first subject enrollment in a Phase I clinical trial for a new drug (human interferon α1b inhalation solution). It includes details about the drug, clinical trial approval, and risk warnings. The document is short (1079 characters) and does not contain financial statements, earnings data, or detailed financial analysis. It is an operational update related to clinical trial progress rather than a financial report or regulatory filing about financial results. It is not a report publication announcement since it does not mention any report being published or attached. The content fits best under a general regulatory announcement category about company operations and clinical progress. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2023-01-10 Chinese
关于公司2023年向银行等金融机构申请融资额度的公告
Capital/Financing Update Classification · 100% confidence The document is a public announcement by the company regarding its plan to apply for a new financing credit line from banks and financial institutions. It details the amount, purpose, and collateral for the financing, as well as authorization for legal representatives to sign related documents. There is no financial statement, earnings data, or detailed financial analysis presented. The document is short (852 characters) and serves as an update on capital/financing activities rather than a full financial report or regulatory filing. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2023-01-05 Chinese
中信建投证券股份有限公司关于科兴生物制药股份有限公司2023年度日常关联交易额度预计的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from a sponsoring institution (中信建投证券股份有限公司) regarding the expected daily related-party transaction limits for the year 2023 of 科兴生物制药股份有限公司. It includes detailed financial data, descriptions of related parties, transaction categories, amounts, and compliance with regulatory rules. The document is not a full annual or interim report but rather a specialized audit or verification report focused on related-party transactions and their compliance. It does not announce or summarize earnings, nor is it a management or board change announcement. It is not a proxy, voting result, or dividend notice. The document fits best as an Audit Report / Information (AR) because it provides audit-related opinions and verification on specific financial transactions and compliance, without being a full annual report or earnings release. FY 2023
2023-01-05 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.